Bullish & Foolish
Full KAPA fundamentals All 466 on the Survival Watch

KAPAKAIROS PHARMA, LTD.

Is Kairos Pharma struggling financially?

Yes, by its own account. Kairos Pharma told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$6.9M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$2.6M

÷

Cash burned over the last 12 months

$6.5M

What Kairos Pharma told the SEC

…since inception and incurred a net loss of $ 1,654 and used cash in operations of $ 1,036 during the three months ended March 31, 2026. These factors raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025 financial statements, has expressed substantial doubt about…

KAIROS PHARMA, LTD., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 30.0% share-count increase The company issued stock. Each share now owns 23.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt